30 closest matches · ranked by relevance
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Myelofibrosis
Primary: Objective Response Rate (ORR) — 1; 9; 1 Participants
MPN (Myeloproliferative Neoplasms)
Primary: Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose — -11.6; -17.4; -22.4; -13.4 Percentage change from baseline — p=0.0250
Primary Myelofibrosis (PMF) · Post Polycythaemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary: Percentage of Participants With Treatment Success — 50 Percentage of participants
Primary Myelofibrosis (MF) · Post-Polycythemia Vera (PV) MF · Post-Essential Thrombocythemia (ET) MF
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24 — 38 Participants — p=0.0007
Myelofibrosis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years — 2153; 830 Participants
Myelofibrosis · Polycythemia Vera · Thrombocytosis
Primary: Number of Participants With Adverse Events (AEs) — 30; 35; 47; 5 participants
Myelofibrosis
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) Myelofibrosis · Postessential Thrombocythemia (Post-ET) Myelofibrosis
Primary: Transfusion Independence Response by Week 24 — 34.1 percentage of subjects
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event — 0; 0; 0; 0 Participants
Myelofibrosis
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 — 28.5; 0 Percentage of Participants — p=<0.0001
MPN (Myeloproliferative Neoplasms)
Primary: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 — 65; 1 participants — p=<0.0001
Myelofibrosis
Primary: Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement) — 14 Participants
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · Primary Myelofibrosis · Secondary Myelofibrosis
Primary: Number of Participants With a Response — 15 Participants
Myelofibrosis
Primary: Efficacy of CC-5013 in Myelofibrosis — 7; 9; 12; 9 Participants
Myelofibrosis
Primary: Percentage of Participants With at Least 1 Adverse Event From Baseline Through Week 16 — 78.0 Percentage of participants
Myelofibrosis
Primary: Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score — 0; 16.7; 6.7; 13.3…
Myelofibrosis
Primary: Number of Patients That Achieve Stable Disease or Clinical Improvement — 3; 4; 1; 3 Participants
Myelofibrosis With Myeloid Metaplasia · Myeloid Metaplasia · Myelofibrosis
Primary: Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment — 55.0; 23.5; 21.1; 47.6 percentage of participants — p=0.092
Essential Thrombocythemia · Polycythemia Vera · Primary Myelofibrosis
Primary: Overall Response Rate — 0.26 Proportion of participants
Primary Myelofibrosis · Post-Polycythemia Vera · Myelofibrosis
Primary: Spleen Volume Response Rate (RR) — 35.8; 6.0 Percentage of Participants — p=<0.0001
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities — 73; 62; 36; 16 Participants
Primary Myelofibrosis · Secondary Myelofibrosis · Myeloid Malignancies
Primary: MF Participants: Percentage of Participants With Overall Response (OR) - (Clinical Improvement[CI] or Partial Remission[PR] or Complete Remission[CR]) Per International…
Leukemia · Myelofibrosis
Primary: Number of Participants With Objective Response — 0; 0; 6 Participants
Myelofibrosis (MF)
Primary: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24) — 31.50; 63.20 percentage of participants — p=<0.0001
Primary Myelofibrosis · Polycythemia Vera · Post-Essential Thrombocythemia Myelofibrosis
Primary: Stage 1 Main Phase: Overall Response Rate (ORR) — 37.5; 14.3; 33.3; 50.0 Percentage of Participants
Myelofibrosis · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Polycythemia Vera · Thrombocythemia
Primary: Number of Participants With Best Overall Response — 0; 3; 6 Participants
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Splenic Response Rate at Week 24 — 57; 64; 158; 153 Participants — p=0.014
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Primary: Splenic Response Rate at Week 24 — 7; 3; 97; 49 Participants — p=0.90